title: Treatment Outcomes of Patients Treated for Pulmonary Tuberculosis after Undergoing Gastrectomy.
abstract: Gastrectomy is a proxy of malnutrition, which may lead to increased risk for developing pulmonary tuberculosis (TB). Malabsorption in gastrectomy patients could lead to low serum levels of rifampicin, which may be related to higher treatment failure. However, there is limited information on treatment outcomes of TB in patients who have undergone gastrectomy. This study aims to determine treatment outcomes and adverse effects in patients treated for TB after undergoing gastrectomy for gastric cancer. During the study period, 112 patients were treated for active TB that developed after gastrectomy for gastric cancer. Among them, we selected 15 patients who were culture positive at initial diagnosis and had evidence of active TB on imaging studies; namely, the remaining 97 patients without initial culture or imaging studies were excluded. We thus performed a case-control study of gastric cancer patients treated for TB after undergoing gastrectomy (n = 15). The control group was defined as age- and sex-matched TB patients who had not received gastrectomy (n = 45). Treatment failure in clinical, microbiological aspects, and adverse events were analyzed. Patients who had undergone gastrectomy exhibited higher 4-month clinical failure rates, compared to non-gastrectomy patient: 4 (26.7%) vs. 1 (2.2%), P = 0.012. Gastrointestinal adverse effects were more frequent in patients with gastrectomy, compared to non-gastrectomy patients: 9 (60%) vs. 5 (11.1%), P < 0.001. In conclusion, patients treated for TB after undergoing gastrectomy are associated with higher rates of gastrointestinal adverse events and treatment failure.
authors.affiliation: Department of Internal Medicine, Yonsei University College of Medicine.
authors.forename: In Young
authors.initials: IY
authors.lastname: Jung
authors.forename: Moo Hyun
authors.initials: MH
authors.lastname: Kim
authors.forename: Woo Yong
authors.initials: WY
authors.lastname: Jeong
authors.forename: Mi Young
authors.initials: MY
authors.lastname: Ahn
authors.forename: Yong Duk
authors.initials: YD
authors.lastname: Jeon
authors.forename: Hea Won
authors.initials: HW
authors.lastname: Ahn
authors.forename: Jin Young
authors.initials: JY
authors.lastname: Ahn
authors.forename: Je Eun
authors.initials: JE
authors.lastname: Song
authors.forename: Dong Hyun
authors.initials: DH
authors.lastname: Oh
authors.forename: Yong Chan
authors.initials: YC
authors.lastname: Kim
authors.forename: Eun Jin
authors.initials: EJ
authors.lastname: Kim
authors.forename: Su Jin
authors.initials: SJ
authors.lastname: Jeong
authors.forename: Nam Su
authors.initials: NS
authors.lastname: Ku
authors.forename: June Myung
authors.initials: JM
authors.lastname: Kim
authors.forename: Jun Yong
authors.initials: JY
authors.lastname: Choi
mesh_terms: D000368:Aged; D000995:Antitubercular Agents / Q000627:therapeutic use; D005260:Female; D005743:Gastrectomy; D006801:Humans; D008297:Male; D008875:Middle Aged; D016896:Treatment Outcome; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000382:microbiology
chemical_list: D000995:Antitubercular Agents